Galectin Therapeutics Inc. 2017 Form 10-K Summary
Business Context and Reporting Period
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company developing galectin inhibitors for fibrotic disease, cancer immunotherapy, and severe skin disease. Its lead candidate, GR-MD-02, is primarily being developed for NASH-related liver fibrosis and compensated cirrhosis. The filing covers the fiscal year ended December 31, 2017, with comparative information for 2016.
The company has no approved products, commercial sales, or operating revenue. Its principal business activity remains research and development, with development programs relying substantially on third-party clinical, manufacturing, and research providers.
Key Financial Metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $11.7 million | $15.3 million | Down 24% |
| General and administrative expense | $4.5 million | $6.2 million | Down 26% |
| Total operating expenses | $16.2 million | $21.5 million | Down 24% |
| Net loss | $16.2 million | $21.4 million | Improved by $5.2 million |
| Net loss attributable to common stockholders | $17.5 million | $22.4 million | Improved by $4.9 million |
| Basic and diluted loss per share | $0.49 loss | $0.76 loss | Improved |
| Net cash used in operations | $15.9 million | $16.4 million | Improved by $0.5 million |
| Cash and cash equivalents at year-end | $3.1 million | $15.4 million | Down $12.3 million |
Operating and profit margins are not meaningful because the company generated no revenue. The accumulated deficit was $181.2 million at December 31, 2017. Total assets were $4.2 million, total liabilities were $3.0 million, and stockholders’ equity was negative $0.5 million.
The company reported no debt borrowings at year-end. In December 2017 it entered into a $10 million unsecured line of credit with director and stockholder Richard E. Uihlein. Borrowings were permitted through December 31, 2018, bear interest at the applicable federal short-term rate, and are due December 31, 2019. No amounts were borrowed in 2017. The company issued warrants to purchase 1 million common shares at $5 per share in connection with the facility.
Financing activities provided $3.6 million in 2017, primarily from common-stock issuances and at-the-market offerings. The company subsequently received $4.5 million from warrant exercises between January 1 and March 1, 2018.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined by $3.6 million as Phase 2 clinical activities, including NASH-CX, were completed.
- General and administrative expense declined by $1.6 million, primarily due to lower legal costs, stock-based compensation, and investor-relations expenses.
- Net loss decreased from $21.4 million to $16.2 million, while loss attributable to common stockholders decreased from $22.4 million to $17.5 million.
- Cash decreased substantially from $15.4 million to $3.1 million because operating cash consumption exceeded financing proceeds.
- Common shares outstanding increased from approximately 32.9 million to 35.8 million during 2017, with additional dilution possible from preferred-stock conversions, options, and warrants.
- GR-MD-02 produced mixed but potentially important NASH-CX results. The primary endpoint showed a trend toward benefit in the total population but was not statistically significant versus placebo. Statistically significant effects were reported in certain subgroups, particularly patients without baseline esophageal varices and at the 2 mg/kg dose.
Clinical Outlook, Guidance, Risks, and Unusual Items
Management planned to meet with the FDA in the second quarter of 2018 to discuss NASH-CX results and a potential Phase 3 program. The company stated that its available cash, the line of credit, and subsequent warrant proceeds were expected to fund currently planned operations through at least March 31, 2019. Additional financing is required thereafter, and failure to obtain funding before that point could require the company to cease operations.
NASH-CX enrolled 162 patients with well-compensated NASH cirrhosis. In the overall population, the primary hepatic venous pressure gradient endpoint did not reach statistical significance. In patients without esophageal varices, the 2 mg/kg dose significantly improved the endpoint and reduced development of new esophageal varices. GR-MD-02 was described as safe and well tolerated during the one-year trial, but the findings require confirmation in later-stage trials.
The earlier NASH-FX pilot trial did not meet its primary biomarker endpoint or secondary liver-stiffness endpoints. Cancer immunotherapy and psoriasis programs remain early-stage or investigator-sponsored and are not the primary focus. The psoriasis study was small, open-label, and uncontrolled; management stated that further development would likely require a strategic partner.
- The company remains dependent on GR-MD-02 and has not demonstrated Phase 3 efficacy or obtained regulatory approval.
- Clinical development, FDA review, manufacturing, reimbursement, and commercialization remain uncertain and costly.
- Management relies on third-party clinical research organizations, trial sites, and contract manufacturers.
- Financing needs create substantial dilution and liquidity risk. Outstanding warrants totaled approximately 13.2 million shares and stock options totaled approximately 5.2 million shares at year-end.
- Preferred stock carries dividend, conversion, liquidation, and governance rights. The 10X Fund and affiliated parties hold significant voting, conversion, nomination, and approval rights.
- Shareholder derivative litigation remained pending on appeal in Nevada. The company could not reasonably estimate potential losses, although it did not believe reasonably possible losses were material based on information available at filing.
- The company reported an accumulated deficit, negative stockholders’ equity, no revenue, and a stated risk that operations may need to cease if additional capital is unavailable.
- The 2017 Tax Cuts and Jobs Act created provisional tax accounting effects, but the company maintained a full valuation allowance against deferred tax assets.
Investor Verification Checklist
- Verify the complete NASH-CX data set, subgroup definitions, statistical analyses, and FDA feedback regarding a Phase 3 design.
- Verify current cash, borrowing availability, warrant exercises, burn rate, and the timing and terms of required additional financing.
- Review dilution from preferred-stock conversion rights, warrants, options, stock-based compensation, and future equity offerings.
- Review whether the $10 million line of credit has been drawn, its remaining availability, interest terms, and related warrant vesting.
- Assess the regulatory and clinical risks associated with GR-MD-02, including the failure of NASH-FX to meet its endpoints and the NASH-CX primary endpoint result.
- Review the status and potential financial impact of the Nevada shareholder litigation and any related securities or governance matters.
- Confirm intellectual-property scope, patent expiration dates, third-party manufacturing arrangements, and strategic-partner requirements.